Vir Biotechnology, Inc. (VIR)
NASDAQ: VIR · Real-Time Price · USD
5.09
-0.33 (-6.01%)
At close: May 9, 2025, 4:00 PM
5.23
+0.14 (2.79%)
After-hours: May 9, 2025, 5:43 PM EDT
Vir Biotechnology Revenue
Vir Biotechnology had revenue of $3.03M in the quarter ending March 31, 2025, a decrease of -94.62%. This brings the company's revenue in the last twelve months to $20.86M, down -73.79% year-over-year. In the year 2024, Vir Biotechnology had annual revenue of $74.21M, down -13.90%.
Revenue (ttm)
$20.86M
Revenue Growth
-73.79%
P/S Ratio
35.48
Revenue / Employee
$51,130
Employees
408
Market Cap
708.47M
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
VIR News
- 12 hours ago - Vir Biotechnology Announces Preliminary 24-Week Post-End of Treatment Data for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B From the MARCH Study - Business Wire
- 1 day ago - Vir Biotechnology: Tobevibart Combination Pushing Forward For Needed HDV Treatment - Seeking Alpha
- 1 day ago - Vir Biotechnology, Inc. (VIR) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 days ago - Vir Biotechnology Provides Corporate Update and Reports First Quarter 2025 Financial Results - Business Wire
- 9 days ago - Vir Biotechnology to Provide Corporate Update and Report First Quarter 2025 Financial Results on May 7, 2025 - Business Wire
- 15 days ago - Vir Biotechnology to Present Latest Clinical Data in Hepatitis Delta and B Programs at the European Association for the Study of the Liver (EASL) Congress 2025 - Business Wire
- 7 weeks ago - Brii Biosciences Provides Corporate Update and Reports Full-Year 2024 Financial Results - PRNewsWire
- 2 months ago - Vir Biotechnology Enrolls First Patient in Phase 3 ECLIPSE Registrational Program for Chronic Hepatitis Delta - Business Wire